Drug safety under the microscope in korean asthma patients
NCT ID NCT05091333
Summary
This study monitored the safety and effectiveness of FASENRA, a medication for severe asthma and a related condition called EGPA, in real-world Korean patients. Doctors observed 51 adults who were starting FASENRA treatment for the first time, following them for up to 48 weeks. The goal was to track any side effects and see how well the drug worked in everyday medical practice, not in a controlled trial.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA, EGPA(EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Busan, South Korea
-
Research Site
Gangneung-si, South Korea
-
Research Site
Seoul, South Korea
-
Research Site
Suwon, South Korea
-
Research Site
Ulsan, South Korea
Conditions
Explore the condition pages connected to this study.